AU - Misra, Bijay AU - Singh, Shivaram TI - Nonalcoholic fatty liver disease and hepatitis B virus infection PT - SHOR DP - 2012 Jan 1 TA - Hepatitis B Annual PG - 86-93 VI - 9 IP - 1 4099- https://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2012;volume=9;issue=1;spage=86;epage=93;aulast=Misra;type=0 4100- https://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2012;volume=9;issue=1;spage=86;epage=93;aulast=Misra AB - Nonalcoholic fatty liver disease [NAFLD] has rapidly emerged as the most common liver disorder not only in developed countries, but also in the developing countries. This entity encompasses a wide variety of liver abnormalities ranging from plain hepatic steatosis through nonalcoholic steatohepatitis [NASH] to cirrhosis of the liver and hepatocellular carcinoma [HCC]. NAFLD is now recognized as the hepatic manifestation of insulin resistance [IR], and an important marker of the metabolic syndrome [MS]. Although a number of advances have been made in elucidating the pathogenetic mechanisms involved in the causation and perpetuation of NAFLD, a great many unanswered questions remain unresolved yet. In view of the involvement of so many different pathways in the pathogenesis, there has always been a speculation regarding the interaction between NAFLD and other liver diseases especially chronic hepatitis C [CHC] and chronic hepatitis B [CHB], because of theubiquitous distribution of NAFLD and its common association with other liver diseases.